Axsome Shares Hit New Low on Auvelity Launch Pace
Axsome Therapeutics stock fell to a 52-week low despite strong third-quarter revenue growth.
Updated on Nov. 3, 2026 in Alzheimer’s
Live Poll
Do you think new Alzheimer's medications are reaching patients faster than before?
Axsome Therapeutics shares fell as much as 15% on Monday to a new 52-week low, closing down 6%. The decline came despite the company reporting third-quarter total net product revenue of $259.7 million, up 52% year-over-year.
Why it matters
Investors focused on the pace of Auvelity's launch in the Alzheimer's disease agitation indication, despite a strong quarterly report. The stock has been pressured as the market weighs how quickly the newly expanded label will translate into prescriptions.
Axsome reported third-quarter total net product revenue of $259.7 million, up 52% from $171.0 million a year earlier, with Auvelity sales in depression and Alzheimer's agitation totaling $208 million. Analysts have not yet seen the prescription inflection they expect, and the launch pace in the Alzheimer's agitation indication remains an open question.
The players
Axsome Therapeutics
Axsome Therapeutics is a U.S. biopharmaceutical company that markets Auvelity, an oral treatment for major depressive disorder and Alzheimer's disease agitation.
Jefferies
Jefferies is a global investment bank whose analysts cover pharmaceutical and biotechnology stocks.
The details
Shares fell as much as 15% intraday Monday, a new 52-week low, and closed down 6%, leaving the stock down 26% year-to-date. Jefferies lowered its price target to $305 from $380 while keeping a Buy rating, and the firm expects Auvelity scripts to inflect in the nearer term. Axsome's net loss narrowed to $12.9 million, or $0.25 per share, from $47.2 million, or $0.94 per share, a year earlier.
Timeline
June 2026: Axsome launched Auvelity in the Alzheimer's disease agitation indication.
Q3 2026: First full quarter of Auvelity sales in Alzheimer's disease agitation was reported.
Monday, November 2, 2026: Axsome shares fell to a new 52-week low.
Health Landscape
Auvelity was first approved for major depressive disorder, and its Alzheimer's disease agitation launch in June 2026 extends the drug into a new, large indication. Whether that expansion delivers the $4 billion to $5 billion in combined peak sales Jefferies forecasts will shape how investors judge the company's broader neuropsychiatry strategy.
Auvelity is an oral medication, so patients and caregivers in the Alzheimer's disease agitation population may find it relevant to discuss with their clinicians. Coverage and prescribing decisions remain with individual physicians and insurers.
The takeaway
Quarterly revenue growth alone does not settle investor questions about a drug's trajectory. Launch pacing in a newly added indication is the metric to watch as prescription data accumulates in coming quarters.
Further reading
For more on the disease driving this launch, see Alzheimer's coverage on Wisevoter.
Live Poll
Do you think new Alzheimer's medications are reaching patients faster than before?
